G-Protein-Coupled receptors signaling pathways in new antiplatelet drug development

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 3, 2015, Pages 500-512

  Gurbel, Paul A ^a   Kuliopulos, Athan ^b   Tantry, Udaya S ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

blood platelet; coronary disease; GTP binding proteins; purinerginc 2Y12 receptor agoists; receptors; thrombin

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ANTITHROMBOCYTIC AGENT; AZD 1283; CANGRELOR; CYCLOOXYGENASE 1; G PROTEIN COUPLED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEINASE ACTIVATED RECEPTOR 1; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; THROMBIN RECEPTOR; TICAGRELOR; UNCLASSIFIED DRUG; P2RY12 PROTEIN, HUMAN; PROTEINASE ACTIVATED RECEPTOR; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ARTICLE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BLOOD FLOW; ENZYME INHIBITION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; IN VIVO STUDY; INTRACELLULAR SIGNALING; NONHUMAN; PHARMACODYNAMIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RISK REDUCTION; THROMBOCYTE FUNCTION; THROMBOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PROTEINASE-ACTIVATED; RECEPTORS, PURINERGIC P2Y12; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 84922260882     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303412     Document Type: Article

References (86)

1. Gurbel PA, Bliden KP, Hayes KM, Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther. 2004;2:535-545. doi: 10.1586/14779072.2.4.535.
2. Takeda S, Kadowaki S, Haga T, Takaesu H, Mitaku S. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett. 2002;520:97-101.
3. Salon JA, Lodowski DT, Palczewski K. The significance of G proteincoupled receptor crystallography for drug discovery. Pharmacol Rev. 2011;63:901-937. doi: 10.1124/pr.110.003350.
4. Offermanns S. Activation of platelet function through G proteincoupled receptors. Circ Res. 2006;99:1293-1304. doi: 10.1161/01. RES.0000251742.71301.16.
5. Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, Roe MT, Kuliopulos A, Moliterno DJ, French PA, Steinhubl SR, Becker RC; 2008 Platelet Colloquium Participants. G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol. 2009;29:449-457. doi: 10.1161/ATVBAHA.108.176388.
6. Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation. 2010;121:569-583. doi: 10.1161/CIRCULATIONAHA.109.853085.
7. Strachan RT, Sun JP, Rominger DH, Violin JD, Ahn S, Rojas Bie Thomsen A, Zhu X, Kleist A, Costa T, Lefkowitz RJ. Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR). J Biol Chem. 2014;289:14211-14224. doi: 10.1074/jbc. M114.548131.
8. Gieseler F, Ungefroren H, Settmacher U, Hollenberg MD, Kaufmann R. Proteinase-activated receptors (PARs) - focus on receptor-receptorinteractions and their physiological and pathophysiological impact. Cell Commun Signal. 2013;11:86. doi: 10.1186/1478-811X-11-86.
9. Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov. 2012;11:69-86. doi: 10.1038/nrd3615.
10. Li D, D'Angelo L, Chavez M, Woulfe DS. Arrestin-2 differentially regulates PAR4 and ADP receptor signaling in platelets. J Biol Chem. 2011;286:3805-3814. doi: 10.1074/jbc.M110.118018.
11. Hechler B, Cattaneo M, Gachet C. The P2 receptors in platelet function. Semin Thromb Hemost. 2005;31:150-161. doi: 10.1055/s-2005-869520.
12. Hechler B, Nonne C, Roh EJ, Cattaneo M, Cazenave JP, Lanza F, Jacobson KA, Gachet C. MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther. 2006;316:556-563. doi: 10.1124/ jpet.105.094037.
13. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409:202-207. doi: 10.1038/35051599.
14. Kim S, Kunapuli SP. P2Y12 receptor in platelet activation. Platelets. 2011;22:56-60. doi: 10.3109/09537104.2010.497231.
15. Zhang J, Zhang K, Gao ZG, et al. Agonist-bound structure of the human P2Y12 receptor. Nature. 2014;509:119-122. doi: 10.1038/nature13288.
16. Zhang K, Zhang J, Gao ZG, et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature. 2014;509:115-118. doi: 10.1038/nature13083.
17. Zhang P, Covic L, Kuliolulos A. Protease-activated receptors. In: Michelson AD, ed. Platelets. 3rd ed. San Diego, CA: Academic Press; 2013:249-259.
18. Brass LF, Newman DK, Wannemacher KM, Zhu L, Stalker TJ. Signal transduction during platelet plug formation. In: Michelson AD, ed. Platelets. San Diego, CA: Academic Press; 2013:367-398.
19. Gachet C. P2Y(12) receptors in platelets and other hematopoietic and nonhematopoietic cells. Purinergic Signal. 2012;8:609-619. doi: 10.1007/ s11302-012-9303-x.
20. Leon C, Ravanat C, Freund M, Cazenave JP, Gachet C. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol. 2003;23:1941-1947. doi: 10.1161/01.ATV.0000092127.16125.E6.
21. Gurbel PA, Bliden KP, Antonino MJ, Gesheff T, Cummings CC, Dubois BV, Herzog WR, Tantry US. Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation. Thromb Res. 2012;129:1-2. doi: 10.1016/j.thromres.2011.07.048.
22. Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets. 2008;19:125-133. doi: 10.1080/09537100701694144.
23. Kotova YN, Ataullakhanov FI, Panteleev MA. Formation of coated platelets is regulated by the dense granule secretion of adenosine 5'diphosphate acting via the P2Y12 receptor. J Thromb Haemost. 2008;6:1603-1605. doi: 10.1111/j.1538-7836.2008.03052.x.
24. Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation. 2012;125:1276-87; discussion 1287. doi: 10.1161/CIRCULATIONAHA.111.031195.
25. Jeong YH, Tantry US, Gurbel PA. Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel. Expert Opin Pharmacother. 2012;13:1771-1796. doi: 10.1517/14656566.2012.704909.
26. Payne CD, Li YG, Small DS, Ernest CS II, Farid NA, Jakubowski JA, Brandt JT, Salazar DE, Winters KJ. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol. 2007;50:555-562. doi: 10.1097/FJC.0b013e3181492209.
27. Gurbel PA, Kereiakes DJ, Tantry US. Ticagrelor for the treatment of arterial thrombosis. Expert Opin Pharmacother. 2010;11:2251-2259. doi: 10.1517/14656566.2010.511175.
28. VAN Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasley PJ. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7:1556-65.
29. Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19:209-219. doi: 10.1177/1074248413511693.
30. Nylander S, Femia EA, Scavone M, Berntsson P, Asztély AK, Nelander K, Löfgren L, Nilsson RG, Cattaneo M. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost. 2013;11:1867-1876. doi: 10.1111/jth.12360.
31. Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, Camoin-Jau L, Paganelli F, Dignat-George F, Guieu R. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014;63:872-877. doi: 10.1016/j.jacc.2013.09.067.
32. van Giezen JJ, Sidaway J, Glaves P, Kirk I, Björkman JA. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther. 2012;17:164-172. doi: 10.1177/1074248411410883.
33. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJ, Jonasson J, Nylander S, Gan LM. Ticagrelor enhances adenosineinduced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013;61:723-727. doi: 10.1016/j.jacc.2012.11.032.
34. Alexopoulos D, Moulias A, Koutsogiannis N, Xanthopoulou I, Kakkavas A, Mavronasiou E, Davlouros P, Hahalis G. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study. Circ Cardiovasc Interv. 2013;6:277-283. doi: 10.1161/CIRCINTERVENTIONS.113.000293.
35. Nanhwan MK, Ling S, Kodakandla M, Nylander S, Ye Y, Birnbaum Y. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol. 2014;34:2078-2085. doi: 10.1161/ATVBAHA.114.304002.
36. Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, van Giezen JJ, Penn MS. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost. 2010;104:609-617. doi: 10.1160/TH09-12-0823.
37. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L; PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544-554. doi: 10.1161/ CIRCULATIONAHA.111.047498.
38. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577-2585. doi: 10.1161/ CIRCULATIONAHA.109.912550.
39. Angiolillo DJ, Curzen N, Gurbel P, Vaitkus P, Lipkin F, Li W, Jakubowski JA, Zettler M, Effron MB, Trenk D. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). J Am Coll Cardiol. 2014;63:1500-1509. doi: 10.1016/j.jacc.2013.11.032.
40. Bhavaraju K, Georgakis A, Jin J, Gartner TK, Tomiyama Y, Nurden A, Nurden P, Kunapuli SP. Antagonism of P2Y12 reduces physiological thromboxane levels. Platelets. 2010;21:604-609. doi: 10.3109/09537104.2010.511684.
41. Paul BZ, Jin J, Kunapuli SP. Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem. 1999;274:29108-29114.
42. Kirkby NS, Leadbeater PD, Chan MV, Nylander S, Mitchell JA, Warner TD. Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost. 2011;9:2103-2105. doi: 10.1111/j.1538-7836.2011.04453.x.
43. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007;115:3156-3164. doi: 10.1161/CIRCULATIONAHA.106.675587.
44. Warner TD, Nylander S, Whatling C. Anti-platelet therapy: cyclooxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol. 2011;72:619-633. doi: 10.1111/j.1365-2125.2011.03943.x.
45. Grześk G, Kozinski M, Tantry US, Wicinski M, Fabiszak T, Navarese EP, Grzesk E, Jeong YH, Gurbel PA, Kubica J. High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells. Biomed Res Int. 2013;2013:928271. doi: 10.1155/2013/928271.
46. Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally JI, Hunt SF, Kindon ND, Teobald BJ, Willis PA, Humphries RG, Leff P, Clegg JA, Smith JA, Tomlinson W. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem. 1999;42:213-220. doi: 10.1021/jm981072s.
47. Huang J, Driscoll EM, Gonzales ML, Park AM, Lucchesi BR. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model. J Pharmacol Exp Ther. 2000;295:492-499.
48. Faxon DP. Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials. Nat Rev Cardiol. 2010;7:124-125. doi: 10.1038/ nrcardio.2009.247.
49. Bhatt DL, Stone GW, Mahaffey KW, et al; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303-1313. doi: 10.1056/ NEJMoa1300815.
50. Angiolillo DJ, Firstenberg MS, Price MJ, et al; BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307:265-274. doi: 10.1001/jama.2011.2002.
51. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res. 2008;121:527-534. doi: 10.1016/j.thromres.2007.05.020.
52. Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost. 2008;6:1153-1159. doi: 10.1111/j.1538-7836.2008.03020.x.
53. Ravnefjord A, Weilitz J, Emanuelsson BM, van Giezen JJ. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Thromb Res. 2012;130:622-628. doi: 10.1016/j.thromres.2012.07.021.
54. Schneider DJ, Agarwal Z, Seecheran N, Keating FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC. Cardiovasc Interv. 2014;7:435-442. doi: 10.1016/j. jcin.2013.08.017.
55. Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Effron MB; SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010;56:1017-1023. doi: 10.1016/j.jacc.2010.02.072.
56. Bach P, Antonsson T, Bylund R, Björkman JA, Österlund K, Giordanetto F, van Giezen JJ, Andersen SM, Zachrisson H, Zetterberg F. Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283. J Med Chem. 2013;56:7015-7024. doi: 10.1021/jm400820m.
57. ?-chloromethylenetetraphosphate. PLoS One. 2014;9:e94780. doi: 10.1371/journal.pone.0094780.
58. Gurbel PA, Jeong YH, Tantry US. Vorapaxar: a novel protease-activated receptor-1 inhibitor. Expert Opin Investig Drugs. 2011;20:1445-1453. doi: 10.1517/13543784.2011.606809.
59. Brass LF, Vassallo RR Jr, Belmonte E, Ahuja M, Cichowski K, Hoxie JA. Structure and function of the human platelet thrombin receptor. Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus. J Biol Chem. 1992;267:13795-13798.
60. Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L, Kuliopulos A. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation. 2006;113:1244-1254. doi: 10.1161/CIRCULATIONAHA.105.587758.
61. Austin KM, Covic L, Kuliopulos A. Matrix metalloproteases and PAR1 activation. Blood. 2013;121:431-439. doi: 10.1182/blood-2012-09-355958.
62. Duvernay M, Young S, Gailani D, Schoenecker J, Hamm HE, Hamm H. Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets. Mol Pharmacol. 2013;83:781-792. doi: 10.1124/mol.112.083477.
63. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW. Protease-activated receptor 1 is the primary mediator of thrombinstimulated platelet procoagulant activity. Proc Natl Acad Sci U S A. 1999;96:11189-11193.
64. Kim S, Foster C, Lecchi A, Quinton TM, Prosser DM, Jin J, Cattaneo M, Kunapuli SP. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood. 2002;99:3629-3636.
65. Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, Boykow G, Hsieh Y, Palamanda J, Agans-Fantuzzi J, Kurowski S, Graziano M, Chintala M. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008;51:3061-3064. doi: 10.1021/jm800180e.
66. Gurbel PA, Bliden KP, Saucedo JF, Suarez TA, DiChiara J, Antonino MJ, Mahla E, Singla A, Herzog WR, Bassi AK, Hennebry TA, Gesheff TB, Tantry US. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. J Am Coll Cardiol. 2009;53:648-657. doi: 10.1016/j.jacc.2008.10.045.
67. Zhang P Covic L, Kuliopulos A. Platelet receptors and drug targets: PAR1, collagen, vWF, thromboxane, and other novel targets. In: Waksman R, Gurbel PA, Giglia MA, eds. Antiplatelet therapy in Cardiovascular Disease. West Susses, United Kingdom: John Wiley and Sons, Ltd; 2014.
68. Wu CC, Hwang TL, Liao CH, Kuo SC, Lee FY, Lee CY, Teng CM. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Thromb Haemost. 2002;87:1026-1033.
69. Wu CC, Teng CM. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur J Pharmacol. 2006;546:142-147. doi: 10.1016/j. ejphar.2006.07.004.
70. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3:1800-1814. doi: 10.1111/j.1538-7836.2005.01377.x.
71. Zhang C, Srinivasan Y, Arlow DH, Fung JJ, Palmer D, Zheng Y, Green HF, Pandey A, Dror RO, Shaw DE, Weis WI, Coughlin SR, Kobilka BK. High-resolution crystal structure of human protease-activated receptor 1. Nature. 2012;492:387-392. doi: 10.1038/nature11701.
72. FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm396585.htm. Accessed August 7, 2014.
73. Kimmelstiel C, Zhang P, Kapur NK, Weintraub A, Krishnamurthy B, Castaneda V, Covic L, Kuliopulos A. Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2011;4:171-179. doi: 10.1161/CIRCINTERVENTIONS.110.959098.
74. Covic L, Singh C, Smith H, Kuliopulos A. Role of the PAR4 thrombin receptor in stabilizing platelet-platelet aggregates as revealed by a patient with Hermansky-Pudlak syndrome. Thromb Haemost. 2002;87:722-727.
75. Dimond P, Carlson K, Bouvier M, Gerard C, Xu L, Covic L, Agarwal A, Ernst OP, Janz JM, Schwartz TW, Gardella TJ, Milligan G, Kuliopulos A, Sakmar TP, Hunt SW III. G protein-coupled receptor modulation with pepducins: moving closer to the clinic. Ann N Y Acad Sci. 2011;1226:34-49. doi: 10.1111/j.1749-6632.2011.06039.x.
76. Covic L, Misra M, Badar J, Singh C, Kuliopulos A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med. 2002;8:1161-1165. doi: 10.1038/nm760.
77. Zhang P, Gruber A, Kasuda S, Kimmelstiel C, O'Callaghan K, Cox DH, Bohm A, Baleja JD, Covic L, Kuliopulos A. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation. 2012;126:83-91. doi: 10.1161/CIRCULATIONAHA.112.091918.
78. Fiessinger JN, Bounameaux H, Cairols MA, Clement DL, Coccheri S, Fletcher JP, Hoffmann U, Turpie AG; TAIPAD Investigators. Thromboxane antagonism with terutroban in peripheral arterial disease: the TAIPAD study. J Thromb Haemost. 2010;8:2369-2376. doi: 10.1111/j.1538-7836.2010.04020.x.
79. Bal Dit Sollier C, Crassard I, Simoneau G, Bergmann JF, Bousser MG, Drouet L. Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc Dis. 2009;28:505-513. doi: 10.1159/000236915.
80. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoüe A, Fratacci MD; PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, doubleblind, parallel-group trial. Lancet. 2011;377:2013-2022. doi: 10.1016/ S0140-6736(11)60600-4.
81. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation. 1994;89:588-595.
82. Guth BD, Narjes H, Schubert HD, Tanswell P, Riedel A, Nehmiz G. Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects. Br J Clin Pharmacol. 2004;58:40-51. doi: 10.1111/j.1365-2125.2004.02083.x.
83. Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005;11:507-514. doi: 10.1038/nm1232.
84. Martin V, Guillermet-Guibert J, Chicanne G, Cabou C, Jandrot-Perrus M, Plantavid M, Vanhaesebroeck B, Payrastre B, Gratacap MP. Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood. 2010;115:2008-2013. doi: 10.1182/blood-2009-04-217224.
85. Jackson SP, Schoenwaelder SM. Antithrombotic phosphoinositide 3-kinase β inhibitors in humans: a 'shear' delight! J Thromb Haemost. 2012;10:2123-2126. doi: 10.1111/j.1538-7836.2012.04912.x.
86. Uemura T, Kawasaki T, Taniguchi M, Moritani Y, Hayashi K, Saito T, Takasaki J, Uchida W, Miyata K. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under highshear stress. Br J Pharmacol. 2006;148:61-69. doi: 10.1038/sj.bjp.0706711.